Skip to main content
ARS Home » Research » Publications at this Location » Publication #70103
Title: TARGETING OF CROSSLINKED MOUSE ERYTHROCYTES BY BS**3 AND DTSSP: SIGNIFICANCE FOR THEIR USE AS CARRIERS.

Author
item JORDAN, JOSE - UNIV ALCALA HENARES SPAIN
item Deloach, John
item LUQUE, JOSE - UNIV ALCALA HENARES SPAIN
item DIEZ, JOSE - UNIV ALCALA HENARES SPAIN

Submitted to: Biochimica et Biophysica Acta
Publication Type: Peer Reviewed Journal
Publication Acceptance Date: 1/5/1996
Publication Date: N/A
Citation: N/A

Interpretive Summary: Scientists have long sought to improve the action of drugs in animals and humans. One such way has been to encapsulate the drug in different kinds of materials. One such material is the red blood cell. This report describes the behavior of chemically treated red blood cells in blood circulation of laboratory animals. A benefit of chemical treatment of the red blood cells is that it gives better control over their ability to keep drugs inside the cell. A second benefit is that certain chemical treatments allow for selective targeting of drugs to either the liver or spleen. All of this is aimed at a better safer drug delivery system for man and animals.

Technical Abstract: Chemical conditions of crosslinking mouse erythrocytes with the crosslinking reagents BS**3 and DTSSP have been studied. Extent of crosslinking is dependent on the concentration of the reagent used. Chemical treatments showed a reduced yield of unlysed cells in the case of cross-linked erythrocytes in comparison to control cells. Similar cell volumes were observed in crosslinked erythrocytes with respect to control erythrocytes. In vivo behavior of these modified erythrocytes revealed prominent targeting of crosslinked erythrocytes to liver. This effect can be modulated by reagent concentration and it is clearly evident when concentrations of 5 mM BS**3 or DTSSP were used. Thus, the action of these crosslinkers renders erythrocytes that are targeted to liver. This finding enables us to consider them as possible carriers to be used to deliver target substances for therapeutic uses.